Cadrenal Therapeutics Statistics
Total Valuation
CVKD has a market cap or net worth of $11.93 million. The enterprise value is $7.92 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CVKD has 2.51 million shares outstanding. The number of shares has increased by 63.48% in one year.
| Current Share Class | 2.51M |
| Shares Outstanding | 2.51M |
| Shares Change (YoY) | +63.48% |
| Shares Change (QoQ) | +3.86% |
| Owned by Insiders (%) | 20.86% |
| Owned by Institutions (%) | 8.06% |
| Float | 1.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.06 |
| P/TBV Ratio | 4.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.72
| Current Ratio | 2.72 |
| Quick Ratio | 2.53 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -260.11% and return on invested capital (ROIC) is -165.32%.
| Return on Equity (ROE) | -260.11% |
| Return on Assets (ROA) | -116.44% |
| Return on Invested Capital (ROIC) | -165.32% |
| Return on Capital Employed (ROCE) | -491.51% |
| Weighted Average Cost of Capital (WACC) | 12.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.31M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.27% in the last 52 weeks. The beta is 1.55, so CVKD's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | -68.27% |
| 50-Day Moving Average | 6.43 |
| 200-Day Moving Average | 10.10 |
| Relative Strength Index (RSI) | 37.71 |
| Average Volume (20 Days) | 45,336 |
Short Selling Information
The latest short interest is 74,726, so 2.98% of the outstanding shares have been sold short.
| Short Interest | 74,726 |
| Short Previous Month | 110,378 |
| Short % of Shares Out | 2.98% |
| Short % of Float | 3.77% |
| Short Ratio (days to cover) | 1.32 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -13.46M |
| Pretax Income | -13.24M |
| Net Income | -13.24M |
| EBITDA | -13.45M |
| EBIT | -13.46M |
| Earnings Per Share (EPS) | -$6.64 |
Full Income Statement Balance Sheet
The company has $4.01 million in cash and n/a in debt, with a net cash position of $4.01 million or $1.60 per share.
| Cash & Cash Equivalents | 4.01M |
| Total Debt | n/a |
| Net Cash | 4.01M |
| Net Cash Per Share | $1.60 |
| Equity (Book Value) | 2.74M |
| Book Value Per Share | 1.17 |
| Working Capital | 2.73M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$12.60 million and capital expenditures -$5,104, giving a free cash flow of -$12.61 million.
| Operating Cash Flow | -12.60M |
| Capital Expenditures | -5,104 |
| Depreciation & Amortization | 6,874 |
| Net Borrowing | n/a |
| Free Cash Flow | -12.61M |
| FCF Per Share | -$5.03 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CVKD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -63.48% |
| Shareholder Yield | -63.48% |
| Earnings Yield | -110.94% |
| FCF Yield | -105.65% |
Analyst Forecast
The average price target for CVKD is $13.00, which is 173.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.00 |
| Price Target Difference | 173.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |